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S U M M A R Y
Objectives: MicroRNA-122 has been shown to be crucial for efﬁcient HCV RNA replication in vitro.
Pretreatment intrahepatic microRNA-122 levels in chronic hepatitis C (CHC) patients have been
associated with the outcomes of interferon therapy. Here, we determined microRNA-122 serum levels in
CHC patients and healthy donors using an absolute quantiﬁcation approach and evaluated the
correlation with liver inﬂammation grades and serum alanine aminotransferase (ALT) levels.
Methods: Serum samples were collected from 105 treatment-naive CHC patients, 11 acute hepatitis
patients, and 33 healthy donors. Serum microRNA-122 was measured using the TaqMan RT-qPCR. The
cycle threshold values were converted to copy numbers by drawing a standard curve using a chemical
synthetic standard. For accurate quantiﬁcation, copy numbers were further normalized according to the
recovery ratios of spiked-in cel-miR-39.
Results: Serum levels of microRNA-122 were signiﬁcantly higher in acute hepatitis and CHC patients
than in healthy donors (p < 0.001). However, there was no signiﬁcant association between microRNA-
122 and ALT serum levels or liver inﬂammation grades.
Conclusions: The present study showed that serum microRNA-122 was elevated in acute and chronic
hepatitis patients. However, this biomarker for acute liver injury did not reﬂect the liver inﬂammation
activity in CHC patients.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Hepatitis C is a global health problem. Approximately 130–200
million people are chronically infected with the hepatitis C virus
(HCV).1–3 Chronic hepatitis C (CHC) is a major cause of cirrhosis,
hepatocellular carcinoma (HCC), and end-stage liver disease.
Different from hepatitis B, many CHC patients may remain
asymptomatic or have mild symptoms for decades, even when
overt end-stage liver disease has developed.4,5 Alanine amino-
transferase (ALT) serum levels remain the most commonly used
marker for the severity of liver injury, but a chronic HCV infection* Corresponding author. Tel.: +86 10 88325566; fax: +86 10 68322662.
** Corresponding author. Tel.: +86 10 58900422; fax: +86 10 88325733.
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http://dx.doi.org/10.1016/j.ijid.2014.09.020
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).may develop with or without ALT abnormalities.6–8 Thus, it is of
great importance to ﬁnd new biomarkers for the early and accurate
diagnosis of liver injury and disease progression in CHC patients.
Recently, studies have been performed to evaluate the potential
of microRNAs as biomarkers for liver injury in various liver
diseases.9–26 Among these studies, microRNA-122 is of particular
interest. MicroRNA-122 is an abundant liver-speciﬁc microRNA,
accounting for approximately 70% of the total hepatic microRNA.27
The HCV genome, in particular, contains microRNA-122 target
sequences, and binding of microRNA-122 to the HCV genome
positively regulates HCV replication.28,29
Since circulating microRNA-122 levels were ﬁrst reported to
predict drug-induced liver injury,16 the potential of microRNA-122
as a biomarker for disease progression in viral hepatitis patients
has been studied. For example, several clinical studies have shown
that there is a signiﬁcant correlation between microRNA-122 and
serum ALT levels in chronic hepatitis B and C patients.15,19,22,30ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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candidate for viral hepatitis-related HCC.17,26 However, a common
problem in circulating microRNA studies is the diversity of the
study population normalization methods, which gives rise to
inconsistent or even conﬂicting results among these studies.31
In this study, we established a method for the absolute
quantiﬁcation of circulating microRNA-122. We then compared
the serum levels of circulating microRNA-122 in CHC patients,
acute hepatitis patients, and healthy donors, and evaluated the
correlation between microRNA-122 and HCV RNA, serum ALT, and
liver inﬂammation grade.
2. Methods
2.1. Patients
One hundred and ﬁve treatment-naive genotype 1 patients
chronically infected with hepatitis C attending the 302 Military
Hospital of China were enrolled in this study. Inclusion criteria
were anti-HCV and HCV RNA-positive, and no previous interferon-
based therapies. Those with HIV or hepatitis B virus (HBV)
co-infections, or autoimmune diseases, were excluded. Serum
samples were collected and stored at 80 8C until analysis.
Serum samples were also collected from 11 inpatients with
acute hepatitis from the Peking University People’s Hospital (six
with acute hepatitis E, four with acute hepatitis B, and one with
acute hepatitis A) and 33 healthy donors who were negative for
hepatitis virus infection and had normal serum ALT levels.
This study was approved by the Ethics Committee for Human
Experimentation at Peking University People’s Hospital (Beijing,
China) and was performed in accordance with the 1975 Declaration
of Helsinki. Written informed consent was provided for sample
collection and subsequent analysis.
2.2. Clinical chemistry, virology tests, and liver histology
ALT and aspartate aminotransferase (AST) were tested using an
automated biochemical analyzer (model 7600; Hitachi, Tokyo,
Japan) in the clinical laboratory of Peking University. Anti-HCV was
tested using a chemiluminescent microparticle immunoassay
(Architect; Abbott Laboratories, Chicago, IL, USA) and HCV was
genotyped using restriction fragment length polymorphism
(RFLP).32 Hepatitis B virus surface antigen (HBsAg) and anti-HIV
were detected using enzyme immunoassays (Abbott Laboratories,
USA; and bioMe´rieux, Boxtel, the Netherlands, respectively).
Serum HCV RNA levels were measured using the RealTime HCV
Reagent (Abbott Laboratories, USA). Liver inﬂammation grades for
the CHC patients were evaluated using the Ishak G scoring
system.33
2.3. Serum total RNA extraction with spiked-in control microRNA
mimic
To normalize the serum RNA extraction efﬁciency, a synthe-
sized Caenorhabditis elegans microRNA mimic (Shanghai Gene-
Chem, Shanghai, China), cel-miR-39, was used as the spike-in
control. Cel-miR-39 (5 fmol) was added to each 200 ml of serum
sample. Total RNA was isolated from serum using the mirVana
PARIS Kit (Ambion, USA) following the manufacturer’s protocol for
the total RNA isolation procedure. Brieﬂy, 200 ml of serum was
mixed with an equal volume of 2 denaturing solution followed by
organic extraction using acid–phenol and chloroform. The aqueous
phase was mixed with 1.25 volumes of room temperature 100%
ethanol. After washing three times, RNA was ﬁnally eluted using
100 ml 95 8C elution solution or nuclease-free water.2.4. Reverse transcription and TaqMan real-time PCR assays of
microRNA
Extracted RNA was reverse-transcribed using the TaqMan
MicroRNA Reverse Transcription Kit and miRNA-speciﬁc stem-
loop primers (Applied Biosystems, USA). The reverse transcription
reaction was as follows: 0.075 ml of 100 mM dNTP, 0.5 ml RT
enzyme (50 U/ml), 0.75 ml 10 RT buffer, 0.094 ml RNAse inhibitor
(20 U/ml), 2.5 ml eluted RNA, and 2.081 ml nuclease-free water.
Reaction conditions were 16 8C for 30 min, 42 8C for 30 min, 85 8C
for 5 min, and 4 8C until the end of the reaction.
Real-time PCR assays of the transcribed cDNA were performed
using the TaqMan MicroRNA assays (Applied Biosystems, USA).
The reaction system was as follows: 10.0 ml universal master mix II
(2), 1.0 ml 20 RealTime probes, 1.0 ml of cDNA, and 8.0 ml of
nuclease-free water. Reaction conditions were 95 8C for 10 min,
followed by 40 cycles at 95 8C for 15 s, and 60 8C for 1 min.
2.5. Generation of standard curves for absolute quantiﬁcation of hsa-
microRNA-122 and spiked-in control cel-miR-39
Synthetic hsa-microRNA-122 and cel-miR-39 (Shanghai Gen-
eChem, Shanghai, China) were serially diluted to ﬁnal concentra-
tions of 200 nM, 20 nM, 2 nM, 0.2 nM, 0.02 nM, 2 pM, 0.2 pM,
0.02 pM, 2 fM, and 0.2 fM. hsa-microRNA-122 and cel-miR-39
serial dilutions were reverse-transcribed and assayed using
real-time PCR analysis concurrently with RNA extracted from
serum samples. Standard curves for hsa-microRNA-122 and
cel-miR-39 were included on each plate of the miRNA TaqMan
assays to convert the cycle threshold (Ct) values of each sample
into the corresponding number of microRNA copies. Thus, the
microRNA extraction efﬁciencies for each sample could be cal-
culated by the yield ratios of added cel-miR-39, to obtain the
absolute serum microRNA-122 quantiﬁcation results.
2.6. Statistical analysis
Results are expressed as the mean  standard deviation (SD).
Comparisons of quantitative data were done using the Student’s t-test
or Spearman correlation analysis, as appropriate. All statistical tests
were two-sided and a p-value of less than 0.05 was considered to
indicate a statistically signiﬁcant difference. The statistical software
package used was GraphPad Prism v. 5.01 for Windows (GraphPad
Software, San Diego, CA, USA).
3. Results
3.1. Serum levels of microRNA-122 were signiﬁcantly higher in acute
hepatitis and chronic hepatitis C patients than in healthy donors
The characteristics of the study subjects are shown in
Table 1. After converting the qPCR Ct values to copies per
microliter of serum (copies/ml), microRNA-122 quantiﬁcation
results were further normalized by yielding ratios of added spike-
in cel-miR-39. Finally, absolute quantiﬁcation results of serum
microRNA-122 were obtained. Median microRNA-122 serum
levels were 4.017 log10 copies/ml (interquartile range (IQR)
3.756–4.327 log10 copies/ml) in healthy donors, 5.121 log10
copies/ml (IQR 4.874–5.537 log10 copies/ml) in CHC patients,
and 6.577 log10 copies/m1 (IQR 5.718–7.335 log10 copies/ml)
in acute hepatitis patients. As shown in Figure 1, serum
microRNA-122 levels were signiﬁcantly higher in both acute
hepatitis and CHC patients than in healthy donors (p < 0.001 and
p < 0.001, respectively). Serum microRNA-122 levels were signiﬁ-
cantly higher in acute hepatitis patients than in CHC patients
(p < 0.001).
Table 1
Patient characteristics
Number, or mean  SD
Chronic hepatitis C patients
Age, years
Mean  SD 44.23  9.18
Median 45
Range 20–64
Sex, male/female 70/35
ALT, U/L
Mean  SD 107.53  245.06
Median 48
Range 5–1812
HCV RNA, IU/ml
Mean  SD 6.12  105 1.23  106
Acute hepatitis patients
Age, years
Mean  SD 45.45  14.24
Median 46
Range 23–68
Sex, male/female 8/3
Baseline ALT, U/L
Mean  SD 977.27  394.12
Median 881
Range 399–1682
Healthy donors
Age, years
Mean  SD 41.82  7.29
Median 42
Range 30–54
Sex, male/female 20/13
ALT, U/L
Mean  SD 24.67  8.60
Median 27
Range 11–38
SD, standard deviation; ALT, alanine aminotransferase; HCV,
hepatitis C virus.
Figure 1. Serum levels of microRNA-122 were signiﬁcantly higher in acute hepatitis
and chronic hepatitis C patients than in healthy donors.
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hepatitis patients
Serum ALT levels in acute hepatitis patients were assayed at
baseline and weekly until the end of therapy. Among these patients
the duration of therapy varied from 9 to 33 days. As shown in
Figure 2A, there was a good correlation between serum microRNA-
122 and baseline ALT levels in these acute hepatitis patients
(Spearman r = 0.8462, p < 0.001). However, no signiﬁcant correla-
tion was observed for ALT and microRNA-122 levels at all time
points combined, as shown in Figure 2B. Although serum ALT
decreased rapidly during therapy, serum microRNA-122 levels
stayed high, as shown in Figure 3. This suggests that dynamicFigure 2. Correlation of serum microRNA-122 with alanine aminotransferase (ALT) leve
levels at baseline in the acute hepatitis group; B, correlation between serum microRNAchanges in serum microRNA-122 levels in acute patients might be
delayed in this population.
3.3. Serum microRNA-122 levels were not correlated with serum ALT
levels, liver inﬂammation activity, or viral load in CHC patients
Of the CHC patients, 58.1% (61/105) had serum ALT below the
upper limit of normal (ULN, 40 U/l). Liver inﬂammation activities in
these CHC patients were assessed using the Ishak G scoring system.
A strong correlation was observed between ALT levels and Ishak G
scores (Spearman r = 0.4386. p < 0.001), as shown in Figure 4.
However, there was no signiﬁcant correlation between serum
microRNA-122 levels and ALT levels (r = 0.07135, p = 0.4695),
or between serum microRNA-122 levels and Ishak G scores
(r = 0.08263, p = 0.4021) (Figure 5A and B, respectively). Although
microRNA-122 has been proposed as a biomarker candidate for
liver injury in several studies, the absolute quantiﬁcation results in
our study showed that the serum level did not reﬂect the liver
inﬂammation activity in CHC patients.
Similar to most previous studies, there was no signiﬁcant
correlation between serum microRNA-122 levels and HCV RNA
levels (r = 0.01692, p = 0.8639); results are shown in Figure 5C.
4. Discussion
The liver-speciﬁc microRNA-122 has been shown to be crucial
for efﬁcient HCV RNA replication in vitro.28,29 In addition,
pretreatment intrahepatic microRNA-122 levels in CHC patients
have been found to be related to the viral responses to interferon
therapy.34 Recently, circulating microRNA-122 has been consid-
ered a potential marker for liver injury and for clinical outcomes inls in acute hepatitis patients. A, correlation between serum microRNA-122 and ALT
-122 and ALT levels at all time points in the acute hepatitis group.
Figure 3. Dynamic changes in serum microRNA-122 in acute hepatitis patients.
Serum microRNA-122 was at high levels during therapy (among the patients, the
period of therapy varied from 9 to 33 days).
Figure 4. Correlation between alanine aminotransferase (ALT) levels and Ishak G
scores in chronic hepatitis C patients. ALT levels were well correlated with Ishak G
scores in chronic hepatitis C patients (Spearman r = 0.4386; p < 0.001).
Figure 5. Correlations of serum microRNA-122 levels with (A) alanine
aminotransferase (ALT) levels, (B) Ishak G scores, and (C) HCV RNA levels in
chronic hepatitis C patients.
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established an absolute quantiﬁcation method for serum micro-
RNA-122 assays. Results showed that serum microRNA-122 levels
were elevated in both acute hepatitis and CHC patients. However,
correlation between serum microRNA-122 and ALT levels was
observed only in acute hepatitis patients and not in CHC patients.
Serum microRNA-122, the candidate biomarker for acute liver
injury, did not reﬂect the liver inﬂammation activity in CHC in
our study.
The lack of correlation between serum microRNA-122 and
ALT levels or liver injury that we found in our study is different
from the results of many recent studies, with the exception of one
study where no signiﬁcant correlation was found between
serum microRNA-122 and ALT levels in hepatitis B patients.35 As
mentioned above, there were problems involved in the circulating
microRNA studies, which caused inconsistent or even conﬂicting
results in similar studies. Circulating microRNA-122 is no exception.
Bihrer et al.15 found that serum microRNA-122 levels were
comparable between CHC patients with persistently normal ALT
levels and healthy volunteers. However, another study19 observed
an 11.6-fold higher microRNA-122 level in CHC patients with
normal ALT levels compared with healthy controls. Qi et al.17 found
that microRNA-122 serum levels were signiﬁcantly higher in HCC
than in chronic hepatitis B patients, while the opposite result was
also reported.26 It was reported recently that serum microRNA-122
levels markedly decreased while ALT signiﬁcantly increased
with increasing ﬁbrosis stage during CHC infection.36 There are
also different opinions on the predictive value of baseline serum
microRNA-122 levels for the responses to antiviral therapy in CHC
patients.20,37These derivations might be due to the different sample sizes or
races of study populations. However, a general problem with the
circulating microRNA assays is the lack of normalization of the
results. There are currently no commonly accepted internal
references for circulating microRNAs. Different methods are used
to normalize the circulating microRNA quantiﬁcation results. U6,
for example, which has frequently been used as the internal control
for serum microRNAs, has been shown to be unstable in the serum
of chronic hepatitis B and HCC patients.38 Thus, an inappropriate
internal control may affect the accuracy of quantiﬁcation. In some
studies, no internal controls were used, and circulating microRNA
levels were simply indicated as the Ct values. Thus, the accuracy of
J.- Wang et al. / International Journal of Infectious Diseases 30 (2015) 52–5656circulating microRNA quantitation results may be affected by
inadequate normalization of data. Most studies have used a
relative quantiﬁcation method instead of an absolute one, which
will, to some extent, limit the ﬁnal clinical application of promising
microRNA candidates.
In the present study, we performed absolute quantiﬁcation of
microRNA-122 levels to determine the microRNA-122 copy
numbers in the serum. The use of cel-miR-39 as a spike-in control
helped to normalize the serum RNA extraction efﬁciency, which
improves the reliability of the results. Results showed that there
was no correlation between serum microRNA-122 levels and ALT
or Ishak G scores in CHC patients. Considering the limited sample
size, validation of these results requires a larger number of clinical
samples. The absolute quantiﬁcation results showed the correla-
tion between microRNA-122 and baseline ALT levels in acute
hepatitis patients. However, serum microRNA-122 remained at
high levels while ALT decreased to normal levels. In future studies,
we will investigate the correlation between microRNA-122 and
ALT in acute liver injury rat models to determine whether the slow
decrease in serum microRNA-122 level is due to the elimination
half-life of microRNAs or if there are more complicated regulatory
mechanisms involved.
In conclusion, absolute quantiﬁcation of serum microRNA-122
showed that serum microRNA-122 levels were signiﬁcantly higher
in acute hepatitis and CHC patients than in healthy donors.
However, there was no signiﬁcant correlation between the serum
microRNA-122 levels and ALT levels or liver inﬂammation grades
in CHC patients.
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